parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in hepatocytes	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 449	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11396

receipt 11405: BOK in dopamine neurons, braak

power: full sample -0.37 (p 0.132, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.37 (p 0.127, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.120, n 18). could be the mix.
skeptic: leave-one-out range -0.49 to -0.28, sign flips 0; without severely affected donors -0.37 (p 0.132, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BOK in dopamine neurons.

case closed: nothing better to follow up.

receipt 11404: BOK in oligodendrocytes, braak

power: full sample +0.01 (p 0.983, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.754, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.06 (p 0.827, n 18). could be the mix.
skeptic: leave-one-out range -0.15 to +0.11, sign flips 5; without severely affected donors +0.01 (p 0.983, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BOK in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts